DOCSLIB.ORG

A Preliminary Studyinto the Sensitivity of Disease Activity Detection by Serial Weekly Magnetic Resonance Imaging in Multiple Sc

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Preliminary Studyinto the Sensitivity of Disease Activity Detection by Serial Weekly Magnetic Resonance Imaging in Multiple Sc JYournal ofNeurology, Neurosurgery, and Psychiatry 1996;60:339-341 339 SHORT REPORT A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis M Lai, T Hodgson, M Gawne-Cain, S Webb, D MacManus, W I McDonald, A J Thompson, D H Miller Abstract lesion activity is increased by acquiring Long TR and gadolinium enhanced spin enhanced images in addition to standard long echo brain MRI was performed weekly for TR scans. three months in three patients with Two important questions arising are: (1) relapsing-remitting or secondary pro- does increasing the frequency of MRI detect gressive multiple sclerosis. During the more active lesions, thus improving the sensi- study, 38 new enhancing lesions were tivity of the technique for therapeutic monitor- seen; 11 showed enhancement for less ing; (2) do new lesions appearing on monthly than four weeks, and two enhanced on long TR scans without showing gadolinium only one scan. All 16 new lesions seen on enhancement display enhancement at shorter long TR scans showed initial enhance- intervals-evidence that they do would suggest ment. When only every fourth (monthly) that impairment of the blood-brain barrier is scan was analysed, a total of 33 new an obligatory early event in the development enhancing lesions were seen. Subject to of lesions in multiple sclerosis. To consider confirmation in a larger cohort, the these questions, we have performed weekly results suggest: (a) that blood brain bar- MRI for three months in three patients, one rier leakage is an invariable event in new with relapsing-remitting and two with sec- lesion development in relapsing-remitting ondary progressive multiple sclerosis. and secondary progressive multiple scle- rosis; (b) the small increase in sensitivity of weekly scanning does not justify its use Patients and methods in preference to monthly scanning when PATIENT SELECTION monitoring treatments. The patients chosen had to have clinically def- inite multiple sclerosis14 of the relapsing-remit- (7 Neurol Neurosurg Psychiatry 1996;60:339-341) ting or secondary progressive type56 and had to have gadolinium enhancement on their first scan. These criteria were to increase the possi- Keywords: magnetic resonance imaging; multiple bility of a high yield of new gadolinium sclerosis enhancing lesions during the study.1' Of 11 patients screened only three had enhancing Serial brain MRI at monthly intervals has pro- lesions. Thus eight patients did not continue vided valuable insights into the natural history after their first scan. of multiple sclerosis, and is now often used to monitor the efficacy of experimental treat- MRI PROTOCOL Institute of Neurology, 2 enhanced Queen Square, London ments.' Scanning at this interval often shows Informed consent for gadolinium WC1N 3BG,UK asymptomatic new lesions in relapsing-remit- MRI was obtained from each patient before MLai ting or secondary progressive multiple sclero- the commencement of the study. M Gawne-Cain 10 more was given 0 1 mmol/kg S Webb sis, on average five to times often than Each patient D MacManus clinical relapse.3-'0 About 80% of new lesions gadolinium-DTPA intravenously. The MRI W I McDonald on unenhanced conventional long TR spin protocol was then performed as follows: A J Thompson scans enhancement (on Firstly, three sets of pilot scans were per- D H Miller echo show gadolinium Ti weighted spin echo sequences),5 indicat- formed for the purposes of repositioning. Department of Radiology, Royal ing a breach of the blood-brain barrier. These were a Ti weighted sagittal scan, an Hallamshire Hospital, Gadolinium enhancement correlates with axial scan, and a coronal scan. After this an Glossop Road, pathological features of activity-namely, axial fast spin echo sequence was used to Sheffield S1O 2JF, UK T Hodgson perivascular lymphocyte and macrophage infil- acquire long TR scans through the cerebral 3 12 13 and has hemispheres (TR = 1500 ms, TEf = 32/80 Correspondence to: tration and myelin breakdown, Dr DH Miller, NMR Unit, usually ceased at the next monthly follow up ms, slice number 16, slice thickness 5 mm, Institute of Neurology, 24 matrix 256 x 128). Queen Square, London although the associated long TR abnormality field of view cm, WC1 3BG, UK. persists. Foci of enhancement are also often Gadolinium enhanced Ti weighted images Received 3 July 1995 found in the absence of a definite correspond- were then obtained (TR = 500 ms, TE = 14 and in final revised form 5 24 November 1995 ing change on the long TR images." Thus the ms, slice number 16, slice thickness mm, Accepted 30 November 1995 power of MRI in monitoring the effect of field of view 24 cm, matrix 256 x 128). 340 Lai, Hodgson, Gawne-Cain, Webb, MacManus, McDonald, Thompson, Miller Top row: Tl weighted gadolinium enhanced MRIs. Bottom row: equivalent long TR scan acquired in the same study. The sequences show the development of two lesions (A and B). Lesion A enhancesfor one scan only with changes on the long TR scan one week later. Lesion B continued to enhance on six scans. A new lesion appeared on the long TR scan simultaneously with the enhancement. Thirteen weekly studies were performed with EDSS was 6. Further decline was observed the above protocol on each patient. Lesion during the study and the final EDSS was 7. activity was reported from hard copies by two Patient 3 (aged 40 years) had secondary radiologists (TH, MG-C). progressive multiple sclerosis. The initial EDSS was 7. She had no further decline during the study. Results CLINICAL DATA MRI DATA Patient 1 (aged 38 years) had relapsing-remit- The weekly gadolinium enhanced scans were ting multiple sclerosis. At the start of the study reviewed first. During follow up, 38 new her expanded disability status scale (EDSS)'5 enhancing lesions appeared. Thirteen were score was 6. She had one mild relapse in the still enhancing on the final scan. Of these 13, fourth week of the study. At the end of the enhancement was present on six scans in one study her EDSS score was still 6. lesion, five scans in two, four scans in three, Patient 2 (aged 35 years) had secondary three scans in one, two scans in three, and the progressive multiple sclerosis. The initial final scan only in three. Of the 25 new enhancing lesions which could be followed up from the beginning to Duration of enhancement of the 25 lesions in which enhancement could befollowedfrom the end of enhancement, 11 (44%) enhanced the beginning to the end for less than one month (on three scans or Week ofstudy less). Two lesions enhanced on just one scan 8 9 10 11 12 13 (figure). Lesion number 1 2 3 4 5 6 7 To compare the sensitivity of weekly and 1 x x x x x x monthly scanning, the first, fifth, ninth, and 2 x x x x x 3 x x x x x 13th scans were considered to be the monthly 4 x x x for this study. These scans showed 33 5 x x x x x scans 6 x x x new enhancing lesions. Thus monthly scan- 7 x x x x x x ning would have missed only five of 38 (13%) 8 x x x x x x x 9 x x x new enhancing lesions detected on weekly 10 x x x x x x x scans (see table: lesions 6, 12, 14, 24, and 25). 11 x x x x x x 12 x x x The weekly proton density and T2 weighted 13 x x x x x (long TR) scans were then reviewed without 14 x x 15 x x reference to the enhanced images. A total of 16 x x x x 16 new lesions was seen. The images were 17 x x x x x 18 x x x x x x x x x x then compared with the weekly enhanced 19 x x x x x x x scans, and it was apparent that all the new 20 x 21 x x x lesions on long TR scans displayed gadolinium 22 x x x x enhancement at their first appearance. 23 x x x 24 x However, two of the new lesions on long TR 25 x x x were no longer enhancing on the next Weeks 1, 5, 9, and 13 are shaded and simulate the analysis points of the "monthly" scans. An "monthly" scan. Thus monthly scanning " x " indicates the presence of enhancement of a lesion. Thus at the monthly time points the showed 35 new lesions, 33 enhancing and two enhancement of lesions 6, 12, 14, 24, and 25 would have been missed. However, lesions 12 and 24 could be clearly seen as new lesions on the long TR scan. not (see table: lesions 12 and 24), whereas A preliminary study into the sensitivity ofdisease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis 341 weekly scanning showed 38 new lesions, all An alternative explanation is that there is a low enhancing. grade leak to the blood-brain barrier which is not detectable using standard doses of contrast. Pathologically, low grade inflammation is Discussion indeed seen in primary progressive multiple This study of three patients with relapsing- sclerosis'7 and a recent study using a higher remitting (one patient) or secondary progres- dose of contrast agent (03 mmol/kg Gd- sive (two patients) multiple sclerosis was DTPA) has disclosed a substantial increase in intended to compare the sensitivity of weekly the number of enhancing lesions.'9 versus monthly brain MRI in detecting active The role of the blood-brain barrier in the lesions in multiple sclerosis, and to elucidate development of new lesions and its relation to the consistency with which leakage of the the patient's clinical state are important issues blood-brain barrier occurs in the initial stages which need to be considered.
Load more

Recommended publications
  • Safety Data Sheet
    SAFETY DATA SHEET Creation Date 22-Sep-2009 Revision Date 24-Jun-2020 Revision Number 4 1. Identification Product Name Diethylenetriaminepentaacetic acid Cat No. : AC114320000; AC114320010; AC114320050; AC114322500 CAS-No 67-43-6 Synonyms (Carboxymethylimino)bis(ethylenenitrilo)tetraacetic acid; DTPA; Pentetic acid Recommended Use Laboratory chemicals. Uses advised against Food, drug, pesticide or biocidal product use. Details of the supplier of the safety data sheet Company Fisher Scientific Company Acros Organics One Reagent Lane One Reagent Lane Fair Lawn, NJ 07410 Fair Lawn, NJ 07410 Tel: (201) 796-7100 Emergency Telephone Number For information US call: 001-800-ACROS-01 / Europe call: +32 14 57 52 11 Emergency Number US:001-201-796-7100 / Europe: +32 14 57 52 99 CHEMTREC Tel. No.US:001-800-424-9300 / Europe:001-703-527-3887 2. Hazard(s) identification Classification This chemical is considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200) Acute Inhalation Toxicity - Dusts and Mists Category 4 Serious Eye Damage/Eye Irritation Category 2 Reproductive Toxicity Category 2 Specific target organ toxicity - (repeated exposure) Category 2 Inhalation Label Elements Signal Word Warning Hazard Statements Causes serious eye irritation Harmful if inhaled Suspected of damaging fertility or the unborn child May cause damage to organs through prolonged or repeated exposure ______________________________________________________________________________________________ Page 1 / 7 Diethylenetriaminepentaacetic acid Revision
    [Show full text]
  • Nitric Oxide Modulation of Interleukin-1Я-Evoked Intracellular
    The Journal of Neuroscience, December 15, 2000, 20(24):8980–8986 Nitric Oxide Modulation of Interleukin-1␤-Evoked Intracellular Ca2؉ Release in Human Astrocytoma U-373 MG Cells and Brain Striatal Slices Antonella Meini,1 Alberto Benocci,1 Maria Frosini,1 Gianpietro Sgaragli,1 Gianpaolo Pessina,2 Carlo Aldinucci,2 Gise` le Tchuisseu Youmbi,1 and Mitri Palmi1 1Istituto di Scienze Farmacologiche and 2Istituto di Fisiologia, Universita` di Siena, 53100 Siena, Italy Intracellular Ca 2ϩ mobilization and release into mammal CSF Ca 2ϩ release induced by 2.5 but not 10 ng/ml IL-1␤. Ruthenium plays a fundamental role in the etiogenesis of fever induced by red (50 ␮M) and, to a lesser extent, heparin (3 mg/ml) antagonized the proinflammatory cytokine interleukin-1␤ (IL-1␤) and other IL-1␤-induced Ca 2ϩ release, and both compounds administered pyrogens. The source and mechanism of IL-1␤-induced intracel- together completely abolished this response. Similar results were lular Ca 2ϩ mobilization was investigated using two experimental obtained in human astrocytoma cells in which IL-1␤ elicited a models. IL-1␤ (10 ng/ml) treatment of rat striatal slices preloaded delayed (30 min) increase in intracellular Ca 2ϩ concentration 45 2ϩ 2ϩ Ϯ with Ca elicited a delayed (30 min) and sustained increase ([Ca ]i ) (402 71.2% of baseline), which was abolished by 1 45 2ϩ (125–150%) in spontaneous Ca release that was potentiated mML-NAME. These data indicate that the NO/cGMP-signaling by L-arginine (300 ␮M) and counteracted by N-␻-nitro-L-arginine pathway is part of the intracellular mechanism transducing IL- 2ϩ methyl ester (L-NAME) (1 and 3 mM).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • FDA Listing of Established Pharmacologic Class Text Phrases January 2021
    FDA Listing of Established Pharmacologic Class Text Phrases January 2021 FDA EPC Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: “(Drug) is a (FDA EPC Text Phrase) indicated for Active Moiety Name [indication(s)].” For each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13.
    [Show full text]
  • (NSP15) Inhibitors: Repurposing FDA-Approved Drugs
    Potential SARS-CoV-2 Nonstructural Protein 15 (NSP15) Inhibitors: Repurposing FDA-Approved Drugs Jason Y Tang1, Igor F. Tsigelny2-4*, Jerry P. Greenberg2, Mark A. Miller2, Valentina L. Kouznetsova2,4 1REHS program, San Diego Supercomputer Center, UC San Diego, La Jolla, California, USA 2San Diego Supercomputer Center, UC San Diego, La Jolla, California., USA 3Department of Neurosciences, UC San Diego, La Jolla, California, USA 4BiAna. San Diego, California, USA *Corresponding author: UC San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0505, USA Email: [email protected] (Orcid ID: 0000-0002-7155-8947) Running Head: NSP-15 inhibitors as COVID-19 Drugs Word Count: 3743 1 Abstract Purpose: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused millions of deaths worldwide, pushing the urgent need for an efficient treatment. Nonstructural protein 15 (NSP15) is a promising target due to its importance for SARS-CoV-2’s evasion of the host’s innate immune response. Methods: Using the crystal structure of SARS-CoV-2 NSP15 endoribonuclease, we developed a pharmacophore model of the functional centers in the NSP15 inhibitor’s binding pocket. With this model, we conducted data mining of the conformational database of FDA-approved drugs. The conformations of these compounds underwent 3D fingerprint similarity clustering, and possible conformers were docked to the NSP15 binding pocket. We also simulated docking of random compounds to the NSP15 binding pocket for comparison. Results: This search identified 170 compounds as potential inhibitors of SARS-CoV-2 NSP15. The mean free energy of docking for the group of potential inhibitors were significantly lower than for the group of random compounds.
    [Show full text]
  • Analytical Methods for the Detection and Quantification of Adcs in Biological Matrices
    pharmaceuticals Review Analytical Methods for the Detection and Quantification of ADCs in Biological Matrices Héloïse Cahuzac and Laurent Devel * Département Médicaments et Technologies pour la Santé (MTS), CEA, INRAE, SIMoS, Université Paris-Saclay, 91191 Gif-sur-Yvette, France; [email protected] * Correspondence: [email protected]; Tel.: +33-1-69-08-95-65 Received: 8 October 2020; Accepted: 11 December 2020; Published: 14 December 2020 Abstract: Understanding pharmacokinetics and biodistribution of antibody–drug conjugates (ADCs) is a one of the critical steps enabling their successful development and optimization. Their complex structure combining large and small molecule characteristics brought out multiple bioanalytical methods to decipher the behavior and fate of both components in vivo. In this respect, these methods must provide insights into different key elements including half-life and blood stability of the construct, premature release of the drug, whole-body biodistribution, and amount of the drug accumulated within the targeted pathological tissues, all of them being directly related to efficacy and safety of the ADC. In this review, we will focus on the main strategies enabling to quantify and characterize ADCs in biological matrices and discuss their associated technical challenges and current limitations. Keywords: antibody–drug conjugates; pharmacokinetics and biodistribution; liquid chromatography coupled to mass spectrometry; ligand-binding assays; in vivo imaging; ex vivo autoradiography 1. Introduction Antibody–drug conjugates (ADCs) consist of a small-molecule drug (payload) covalently bound to a monoclonal antibody via a chemical linker. By merging the specific binding properties of antibodies to the potency of small molecules, ADCs are designed to selectively deliver cell-killing agents to targeted pathogenic tissues, while limiting systemic toxicity.
    [Show full text]
  • Combined Index to USP 41 and NF 36, Volumes 1–5
    Combined Index to USP 41 and NF 36 Abaca-Acety I-1 Combined Index to USP 41 and NF 36, Volumes 1–5 Page citations refer to the pages of Volumes 1, 2, 3, 4 and 5 of USP 41±NF 36. This index is repeated in its entirety in each volume. 1–2302 Volume 1 2303–4414 Volume 2 4415–5658 Volume 3 5659–6698 Volume 4 6699–8228 Volume 5 Numbers in angle brackets such as 〈421〉 refer to chapter numbers in the General Chapters section. and (salts of) chlorpheniramine, Acetate A dextromethorphan, and methyl, 5706 pseudoephedrine, oral powder Acetate buffer, 5676 Abacavir containing at least three of the TS, 5750 oral solution, 19 following, 47 Acetazolamide, 65 sulfate, 23 and (salts of) chlorpheniramine, for injection, 66 tablets, 20 dextromethorphan, and oral suspension, 68 and lamivudine tablets, 21 pseudoephedrine, oral solution tablets, 68 Abiraterone containing at least three of the Acetic acid, 5181, 5664 acetate, 24 following, 49 ammonium acetate buffer TS, 5750 acetate tablets, 26 and (salts of) chlorpheniramine, diluted, 5181, 5664, 5690 Absolute dextromethorphan, and double-normal (2 N), 5762 alcohol, 5666 pseudoephedrine, tablets containing at glacial, 69, 5664, 5697 ether, 5664 least three of the following, 51 glacial, TS, 5750, 5754 Absorbable chlorpheniramine maleate, and and hydrocortisone otic solution, 2062 dusting powder, 1457 dextromethorphan hydrobromide irrigation, 69 gelatin film, 1929 tablets, 53 metaphosphoric, TS, 5756 gelatin sponge, 1929 and codeine phosphate capsules, 55 otic solution, 70 surgical suture, 3901 and codeine phosphate
    [Show full text]
  • Combatting Wound Biofilm and Recalcitrance with a Novel Anti- Biofilm Hydrofiber Wound Dressing
    Accepted Manuscript Title: Combatting Wound Biofilm and Recalcitrance with a Novel Anti-biofilm Hydrofiber Wound Dressing Author: Philip G. Bowler David Parsons PII: S2213-9095(16)30020-9 DOI: http://dx.doi.org/doi:10.1016/j.wndm.2016.05.005 Reference: WNDM 79 To appear in: Received date: 6-5-2016 Accepted date: 9-5-2016 Please cite this article as: Philip G.Bowler, David Parsons, Combatting Wound Biofilm and Recalcitrance with a Novel Anti-biofilm Hydrofiber Wound Dressing, Wound Medicine http://dx.doi.org/10.1016/j.wndm.2016.05.005 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Title: Combatting Wound Biofilm and Recalcitrance with a Novel Anti- biofilm Hydrofiber Wound Dressing Authors: Philip G Bowler, MPhil David Parsons, PhD Address: ConvaTec GDC, First Avenue, Deeside Industrial Park, Deeside, Flintshire, UK, CH5 2NU Email/Correspondence: [email protected] 1 ABSTRACT Background: Biofilm is an impediment to wound healing as a consequence of its proven ability to impair epithelialization, granulation tissue formation and normal inflammatory processes, as well as protecting wound pathogens from antibiotics and antiseptics. With this in mind, a project was initiated to develop a combined anti-biofilm/antimicrobial technology that could be incorporated into a wound dressing to maximize effectiveness against wound pathogens existing in their predominant biofilm form.
    [Show full text]
  • Edta Ethylene Diamine Tetra Acetic Acid
    EDTA GENERAL Chelation is a chemical combination with a metal in complexes in which the metal is part of a ring. Organic ligand is called chelator or chelating agent, the chelate is a metal complex. The larger number of ring closures to a metal atom is the more stable the compound. This phenomenon is called the chelate effect; it is generally attributed to an increase in the thermodynamic quantity called entropy that accompanies chelation. The stability of a chelate is also related to the number of atoms in the chelate ring. Monodentate ligands which have one coordinating atom like H 2O or NH 3 are easily broken apart by other chemical processes, whereas polydentate chelators, donating multiple binds to metal ion, provide more stable complexes. Chlorophyll, green plant pigment, is a chelate that consists of a central magnesium atom joined with four complex chelating agent (pyrrole ring). The molecular structure of the chlorophyll is similar to that of the heme bound to proteins to form hemoglobin, except that the latter contains iron(II) ion in the center of the porphyrin. Heme is an iron chelate. Chelation is applied in metal complex chemistry, organic and inorganic chemistry, biochemistry, and environment protection. It is used in chemotherapeutic treatments for metal poisoning. Chelating agents offers a wide range of sequestrants to control metal ions in aqueous systems. By forming stable water soluble complexes with multivalent metal ions, chelating agents prevent undesired interaction by blocking normal reactivity of metal ions. EDTA (ethylenediamine tetraacetate) is a good example of common chelating agent which have nitrogen atoms and short chain carboxylic groups.
    [Show full text]
  • Hemumurta Unhau
    HEMUMURTAUS 20170365883A1UNHAU ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2017/ 0365883 A1 Luski et al. ( 43) Pub . Date : Dec . 21 , 2017 ( 54 ) LITHIUM ION BATTERY ( 52 ) U . S . CI. CPC .. HOIM 10 / 4235 ( 2013 .01 ) ; HOIM 10 /0525 (71 ) Applicants :GM GLOBAL TECHNOLOGY ( 2013 .01 ) ; HOIM 2 / 1653 ( 2013 .01 ) ; HOIM OPERATIONS LLC , DETROIT , MI 2 / 166 (2013 .01 ) (US ) ; Bar - Ilan University , Ramat Gan ( IL ) ( 57 ) ABSTRACT (72 ) Inventors : Shalom Luski, Rehovot ( IL ) ; Doron Aurbach , Bnei Brak ( IL ) ; Bob R . A lithium ion battery includes a positive and a negative Powell, JR ., Birmingham , MI (US ) ; Ion electrode , and a nanoporous or microporous polymer sepa C . Halalay , Grosse Pointe Park , MI rator soaked in electrolyte solution and disposed between the (US ) ; Timothy J . Fuller, Pittsford , NY electrodes . At least two different chelating agents are (US ) ; Anjan Banerjee , West Bengal included and selected to complex with : i ) two or more State ( IN ) ; Baruch Ziv , Ramat -Gan different transition metal ions ; ii ) a transition metal ion in ( IL ) ; Yuliya Shilina , Bat Yam ( IL ) two or more different oxidation states ; or iii ) both i ) and ii ) . The at least two different selected chelating agents are to (21 ) Appl. No. : 15 / 186 , 526 complex with transition metal ions in a manner sufficient to (22 ) Filed : Jun . 19 , 2016 not affect movement of lithium ions across the separator during operation of the battery . The chelating agents are : Publication Classification dissolved or dispersed in the electrolyte solution ; grafted (51 ) Int . Cl. onto the polymer of the separator ; attached to the binder HOIM 10 /42 ( 2006 .
    [Show full text]
  • Overview of Role of Radionuclides in Scanning the Brain in Health and Disease
    Journal of Neurology & Stroke Overview of Role of Radionuclides in Scanning the Brain in Health and Disease Preface Review Article revolutionary technique called Computerised Axial Tomography Volume 6 Issue 4 - 2017 (CAT)When Scan GN in Hounsfield1972, it was announced thought that the nuclear development imaging ofwill a get relegated to the pages of history. Since then the world has witnessed the development of MRI, spiral CT, 3-D reconstruction Professor and Head of Anatomical Sciences, All Saints etc. Though the role of nuclear imaging has decreased with the University, St. Vincent and the Grenadines advent of these techniques, it still occupies a niche for itself which cannot be usurped. In this article radio-nuclide scans of the brain *Corresponding author: Sanjoy Sanyal, Professor and Head of Anatomical Sciences, Neuroscientist and Surgeon, Austin Pond Drive, Cary, North Carolina, NC 27519, USA, Email: Isotopeswill be briefly and reviewed. Imaging Received: October 14, 2016 | Published: April 17, 2017 Though radio-isotopes 73As (Arsenic), 197Hg and 203Hg (Mercury) have been used for brain scanning, Technitium pertechnetate (99mTc-pertechnetate) is most commonly used. Following intravenous (IV) injection its gamma ray emissions are Table 1: Radio-isotopes in brain scan. captured by a gamma camera. The scanned image may be seen on a digital screen or on a developed photographic plate, where 99mTcO (pertechnetate) 4 All space occupying lesions increased or decreased gamma emissions correspond to areas of 99mTc-DTPA (pentetate) ‘hot’
    [Show full text]
  • Dissolvine® DZ-P Pentetic Acid - Meets the Chemical Specification Requirements of the USP
    Product Data Leaflet Dissolvine® DZ-P Pentetic Acid - meets the chemical specification requirements of the USP Chemical Name Diethylenetriaminepentaacetic acid Chemical formula DTPA-H5 Structure O O HO C CH 2 CH2 C OH N CH CH CH 2 CH2 N 2 2 N HO C CH 2 CH2 CH2 C OH O C-OH O O Mol. Weight 393.4 CAS Number 67-43-6 Specifications Checkpoint Specification Units Method Identification (IR test) Passes test USP Assay as DTPA-H5 98.0 - 100.5 % USP Residue on ignition 0.2 max % USP Heavy metals as Pb 0.005 max % USP Iron 0.01 max % USP Nitrilotriacetic acid < 0.1 % USP Main Characteristics Dissolvine® DZ-P is a high purity sequestering agent, forming very stable water soluble complexes with polyvalent metal ions in a wide pH range. Solubility in water : approx. 5 g/l water (20°C) : approx. 13 g/l water (50°C) : approx. 48 g/l water (80°C) Addition of alkali hydroxide changes solubility considerably Bulk density untapped (poured) : approx. 500-700 kg/m3 Bulk density tapped : approx. 850-1050 kg/m3 Sequestering values for Dissolvine® DZ-P are approximately (theoretical calculated figures – mg metal ion / g DZ-P): ® Metal ion pH range Dissolvine DZ calcium 6 - 14 100 copper 2 - 14 160 ferric 1 - 11 140 magnesium 6 - 12 60 manganese 4 - 13 140 zinc 2 - 13 165 FPD 1201-07-4, Feb-2012 / Update 1 The information presented herein is true and accurate to the best of our knowledge, but without any guarantee unless explicitly given.
    [Show full text]